Treatment and predictors of outcome in dogs with immune-mediated thrombocytopenia
Authors:
- Armelle M. DelaforcadeADArmelle M. Delaforcade
- Scott P. ShawSSScott P. Shaw
- 1 February 2011
- journal article
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 238 (3) , 346-352
Abstract
Objective—To characterize the clinical course of disease and identify prognostic indicators for immune-mediated thrombocytopenia in dogs. Design—Retrospective cohort study. Animals—73 dogs treated for immune-mediated thrombocytopenia at the Foster Hospital for Small Animals at the Tufts Cummings School of Veterinary Medicine and the Tufts Veterinary Emergency Treatment and Specialties Hospital. Procedures—Medical records from the period of January 2002 through June 2008 were reviewed to identify dogs with a diagnosis of immune-mediated thrombocytopenia. Data collected included signalment, clinical signs, results of initial diagnostic tests, treatment, complications, and survival duration. Results—Dog ages ranged from 5 months to 15 years (median, 8.1 years). Cocker Spaniels were overrepresented, compared with their distribution in the entire hospital population during the same period. Sixty-one of the 73 (84%) dogs survived to discharge. Seven (11 %) of those dogs were lost to follow-up. Five of the remaining 54 (9%) dogs had a relapse of the disease. The presence of melena or high BUN concentration at admission to the hospital was significantly correlated with a decreased probability of survival. Conclusions and Clinical Relevance—Immune-mediated thrombocytopenia is a serious yet treatable disease, which may have a lower rate of recurrence than previously reported. The presence of melena or high BUN concentration in the study suggested a poor prognosis for affected dogs.Keywords
This publication has 20 references indexed in Scilit:
- Underlying diseases and clinicopathologic variables of thrombocytopenic dogs with and without platelet-bound antibodies detected by use of a flow cytometric assay: 83 cases (2004–2006)Journal of the American Veterinary Medical Association, 2009
- Innate Immunity and Host Defense Peptides in Veterinary MedicineJournal of Veterinary Internal Medicine, 2008
- Diagnostic use of cytologic examination of bone marrow from dogs with thrombocytopenia: 58 cases (1994–2004)Journal of the American Veterinary Medical Association, 2007
- Detection of Activated Platelets in Dogs with Primary Immune-Mediated Hemolytic AnemiaJournal of Veterinary Internal Medicine, 2006
- Corticosteroids Versus Intravenous Immune Globulin for the Treatment of Acute Immune Thrombocytopenic Purpura in Children: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsThe Journal of Pediatrics, 2005
- Prognostic Factors for Mortality and Thromboembolism in Canine Immune-Mediated Hemolytic Anemia: A Retrospective Study of 72 DogsJournal of Veterinary Internal Medicine, 2002
- Canine Idiopathic Thrombocytopenic PurpuraJournal of Veterinary Internal Medicine, 1996
- Epidemiologic Survey of Thrombocytopenia in Dogs: A Report on 987 CasesVeterinary Clinical Pathology, 1991
- Therapy of Immune Mediated ThrombocytopeniaJournal of Veterinary Internal Medicine, 1990
- Frequency of renal impairment in paracetamol overdose compared with other causes of acute liver damage.Journal of Clinical Pathology, 1977